More specifically, inhibitors of dihydrooratate dehydrogenase (DHODH), an enzyme located in the inner membrane of the mitochondria that catalyses the fourth step of de novo pyrimidine synthesis, have emerged as therapeutic targets in AML and MM. Here, DHODH is linked to acute myeloid leukemia.